Skip to content

Effect of Low-Dose Esketamine Combined with Different Administration Routes of Fascia Iliaca Compartment Block on Early Postoperative Quality of Recovery in Elderly Patients Undergoing Total Knee Arthroplasty

Effect of Low-Dose Esketamine Combined with Different Administration Routes of Fascia Iliaca Compartment Block on Early Postoperative Quality of Recovery in Elderly Patients Undergoing Total Knee Arthroplasty

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2600123154
Enrollment
Unknown
Registered
2026-04-22
Start date
2026-05-06
Completion date
Unknown
Last updated
2026-04-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Knee-related diseases requiring total knee arthroplasty (TKA)

Interventions

Adjuvant group:During the fascia iliaca compartment block, 40 ml of 0.25% ropivacaine mixed with 0.2 mg/kg esketamine was injected. Ten minutes before skin incision following anesthesia induction, 10
Intravenous administration group:During the fascia iliaca compartment block, 40 ml of 0.25% ropivacaine was injected. Ten minutes before skin incision following anesthesia induction, 10 ml of 0.2 mg/k
Control group:During the fascia iliaca compartment block, 40 ml of 0.25% ropivacaine was injected. Ten minutes before skin incision following anesthesia induction, 10 ml of normal saline was administe

Sponsors

Fuyang Hospital of Anhui Medical University.
Lead Sponsor

Eligibility

Sex/Gender
All
Age
65 Years to 85 Years

Inclusion criteria

Inclusion criteria: 1. Patients scheduled for elective total knee arthroplasty under laryngeal mask general anesthesia combined with fascia iliaca compartment block, with ASA classification I-III; 2. Aged 65-85 years; 3. BMI 18-30 kg/m²; 4. Normal communication ability; 5. Willing to participate and have signed the informed consent form.

Exclusion criteria

Exclusion criteria: 1. Hepatic, renal, or pulmonary insufficiency, or cardiac function class III or IV; 2. Contraindications to nerve block, including allergy to local anesthetics, damage or infection at the puncture site, or coagulation disorders; 3. History of mental disorders or central nervous system diseases, or hearing or visual impairment that prevents cooperation with scale assessments; 4. Contraindications to esketamine, including high risk of severe elevation of blood pressure or intracranial pressure, allergy to esketamine, or mental disorders.

Design outcomes

Primary

MeasureTime frame
The QoR-15 scores;

Secondary

MeasureTime frame
The NRS pain scores at rest.;Total number of PCIA demands;The incidence of nausea and vomiting within 48 hours postoperatively was recorded.;Time to first ambulation postoperatively;The intraoperative dosages of propofol and remifentanil, operative time, and recovery time (time from cessation of drug infusion to eye opening) were recorded.;NRS pain score during activity;Number of effective PCIA demands;Duration of postoperative hospitalization;Remifentanil consumption;Operative time;Recovery time (time from cessation of drug infusion to eye opening);

Countries

China

Contacts

Public ContactZhang Dan

Fuyang Hospital of Anhui Medical University

wfy111407@fy.ahmu.edu.cn+86 153 9965 8297

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: May 1, 2026